STATEMENT OF NEED/TARGET AUDIENCE

Colorectal cancer is among the most common types of cancer in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in the indications, doses and schedules for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Select medical and surgical treatment regimens for patients with colorectal cancer, based on key clinical and pathological risk factors.
• Develop an evidence-based algorithm for the initial treatment for localized Stage II and Stage III colon cancer, in the context of the risks and benefits of adjuvant systemic therapy.
• Assess emerging clinical research information and ongoing trials to decide on the value of continuing molecular-targeted therapy beyond disease progression.
• Evaluate existing data and emerging research on the optimal management of locally advanced rectal cancer, including pre- and postoperative concomitant chemoradiation therapy and additional adjuvant systemic therapy, and incorporate relevant information into management strategies.
• Review the multiple sequential treatment approaches for recurrent or de novo advanced colorectal cancer:
  − Describe the benefits and risks of single-agent and combination chemotherapy regimens.
  − Critically evaluate the current data integrating VEGF and/or EGFR-inhibiting agents into the treatment algorithm.
• Discuss the risks and benefits of neoadjuvant or adjuvant systemic therapy for colorectal cancer with appropriate patients with potentially curable hepatic metastases.
• Counsel appropriately selected patients about clinical trial participation.

PURPOSE OF THIS ISSUE

The purpose of this program is to support the learning objectives by offering the perspectives of Drs Goldberg, Grothey, Haller, Hochster, Meropol, O’Connell and Venook on the integration of emerging clinical research data into the management of colorectal cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should listen to the CD, review the Internet content and complete the Educational Assessment and Credit form located at www.ColorectalCancerUpdate.com/CME. www.ColorectalCancerUpdate.com/LiveThinkTank contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

This program is supported by educational grants from Genentech BioOncology and Sanofi-Aventis.

Table of Contents

Top of Page